Pharmaceutical companies Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (TSVT) are down in trading at the time of writing. This comes after announcing that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to discuss data supporting the supplemental Biologics License Application (sBLA) for its multiple myeloma therapy Abecma…

#bristolmyerssquibb#bmy#fda#odac#karmma3#futureofbmystock#moderatebuy#holds